June 2022 Publication
“In a PDX model of osteosarcoma…”
“In a PDX model of osteosarcoma…”
2022 Annual Report
“Expected to have the following characters…”
“Expected to have the following characters…”
Sept 2022 Dose Escalation 3 RNS
“Reflects the safety profile and tolerability demonstrated in patients to date”
“Reflects the safety profile and tolerability demonstrated in patients to date”
If you assume T/O multiple of x4. I.e. < half of the industry average (8.9x).
Then just their “3 tumour market” model has a value of $6Bn.
If you assume a 10% CoS, that is valued at $600m.
We’re valued at $334m. 5.5% CoS.
395 days into trial our CoS has gone from 10% > 5.5%.
Then just their “3 tumour market” model has a value of $6Bn.
If you assume a 10% CoS, that is valued at $600m.
We’re valued at $334m. 5.5% CoS.
395 days into trial our CoS has gone from 10% > 5.5%.
If you don’t believe #AVCT can licence 3996 on 395 days of (mechanism of action) data, you aren’t admirably cautious, you haven’t been paying attention.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
